We deliver affordable clinical

trials with quality and speed

RUSSLAN Clinical Research is an independent Anglo-German clinical trial management company offering a range of clinical research services to worldwide clients in the pharmaceutical, biotechnology and medical device industries.

We operate in both established (the United Kingdom and Germany) and emerging clinical trial regions focussing on Russia, the Ukraine, other countries of the former Soviet Union (e.g. Belarus, Georgia) and the Baltic states of Estonia, Latvia and Lithuania, and provide access to one of the most diverse and available patient populations in the world.

Placing clinical trials in our Eastern European countries of operation allows RUSSLAN Clinical Research to achieve very significant cost savings for our clients. Fast and large-scale patient recruitment is another important advantage. To ensure high quality of our Eastern European trials, we carefully select sites and investigators that work to high quality standards with full ICH GCP compliance under close supervision of our German and British clinical research experts.

We enjoy long-standing relationships with a large number of quality sites in Russia, the Ukraine and other CIS countries, and in the Baltic states working in all main therapeutic areas, all with a strong track record of independent and industry-sponsored clinical research. In Germany and the United Kingdom, RUSSLAN Clinical Research co-operates with a network of independent and university-based clinical trial units and have access to considerable clinical research talent and expertise of leading British and German academic centres.

RUSSLAN Clinical Research provides client-tailored services. We are equally happy to work on small projects and take on big contracts as we have an extensive network of colleagues and associates throughout Eastern and Western Europe.

We provide high quality services within tight timelines and at a very competitive rate. Please contact RUSSLAN Clinical Research for FREE feasibility assessment of clinical trials that could be placed in Eastern Europe (Russia, the Ukraine and other CIS countries, the Baltic states) and Western Europe (Germany and the UK)